|
|
|
|
|
|
|
|
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation | BMC Medicine | Full Text
A limitation of our study was the lack of age and stage breakdowns for both the incidence of, and mortality from, ovarian cancer. This limited the analysis in that it was not possible to use the trial evidence to understand the natural history of ovarian cancer and thus to estimate the potential cost-effectiveness of alternative screening strategies, such as different screening intervals or different age ranges.
Background
The United Kingdom
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was the
biggest ovarian cancer screening trial to date. A non-significant effect
of screening on ovarian cancer was reported, but the authors noted a
potential delayed effect of screening, and suggested the need for four
years further follow-up. There are no UK-based cost-effectiveness
analyses of ovarian cancer screening. Hence we assessed the lifetime
outcomes associated with, and the cost-effectiveness of, screening for
ovarian cancer in the UK, along with the value of further research.
Methods
We performed a model-based
economic evaluation. Effectiveness data were taken from UKCTOCS, which
considered strategies of multimodal screening (MMS), ultrasound
screening (USS) and no screening. We conducted systematic reviews to
identify the remaining model inputs, and performed a rigorous and
transparent prospective evaluation of different methods for
extrapolating the effect of screening on ovarian cancer mortality. We
considered costs to the UK healthcare system and measured effectiveness
using quality-adjusted life years (QALYs). We used value of information
methods to estimate the value of further research.
Conclusions
Screening for ovarian cancer
with MMS is both more effective and more expensive than not screening.
Compared to national willingness to pay thresholds, lifetime
cost-effectiveness is promising, but there remains considerable
uncertainty regarding extrapolated long-term effectiveness.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.